drugset / Trial / NCT03809481
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
RandomizedParallel-groupSingle-blindTreatment
Summary
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
Timeline
- Start
- 2019-05-16
- Primary completion
- 2022-06-10
- Completion
- 2022-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Argatroban | Small molecule | 2 ug/kg | — |
| Subject | Danaparoid Sodium | Unknown | 150 iu | Intravenous |
| Subject | Danaparoid Sodium | Unknown | 200 iu | Intravenous |